"**JAK1** is an **intracellular, non-receptor tyrosine kinase** that operates as the receptor-proximal catalytic component of the **JAK–STAT signaling pathway**, transducing extracellular cytokine signals into transcriptional responses. Mechanistically, activated JAKs phosphorylate (i) themselves, (ii) cytokine receptors, and (iii) STAT transcription factors, which then dimerize and enter the nucleus to regulate gene expression."

"- **N-terminus**: a receptor-binding **FERM–SH2 "holodomain"** (FERM + SH2-like domains) mediates association to membrane-proximal receptor motifs."

"A kinase-family classification study explicitly annotates human **JAK1 (P23458)** as EC **2.7.10.2** and delineates two "kinase-like" domains: a **non-catalytic/pseudokinase** region (residues **583–855**) and the **active kinase** region (residues **875–1153**)."

"JAKs are cytosolic kinases that are **anchored near the plasma membrane** by binding to cytokine receptor cytoplasmic motifs; this receptor tethering is mediated by the **FERM** region (and associated SH2-like elements) and positions JAK1 for rapid activation upon receptor engagement/dimerization."

"the **intracellular "box 1" motif** binds the **F2 subdomain** of the FERM module, while **"box 2"** binds the **SH2-like domain**; the combined box1+box2 epitope spans ~**85 Å** and buries **>1000 Ų** of surface area in the receptor–JAK1 interface."

"- **IFN-γ receptor signaling**: **JAK1 + JAK2** leading to STAT1 recruitment/activation (representative example in immunology/cancer context)."

"- **Type I interferons (IFN-α/β)**: **JAK1 + TYK2**."

"- **Common γ-chain cytokines** (e.g., **IL‑2, IL‑4, IL‑7, IL‑21**): **JAK1 + JAK3**."

"- **IL‑6/gp130 signaling**: JAK1 is described as associating with the **gp130** receptor system (a major pro-inflammatory axis)."

"A central regulatory concept is that the **JH2 pseudokinase domain restrains JAK activity** at baseline and is required for proper control of the catalytic JH1 kinase domain. A 2024 structural synthesis notes that deletion of the pseudokinase domain can increase basal kinase activity, supporting an **autoinhibitory** role for JH2."

"A clinical-immunology-focused review lists **JAK1 activation-loop tyrosines Y1022/Y1023** as phosphorylation sites, with **Y1023** reported to be more highly phosphorylated than Y1022—supporting an activation-loop phosphorylation mechanism typical of kinases."

"Cytokine binding induces receptor dimerization/oligomerization that repositions receptor-bound JAKs, shifting JAK1 from an inhibited state to an active configuration (including changes in relative placement/orientation of the JH1 kinase domains)."